Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XWELLSTU:V9G0 27 Days Payable is 55.88 as of Jun. 2026, which is 50% above its 10-year median of 37.19. GuruFocus rates STU:V9G0 with a GF Score™ of 27/100 and a GF Value™ of €2.45. The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, XWELL ranks worse than 62.11% on this metric.
XWELL's average Accounts Payable for the
three
months ended in Jun. 2026 was €2.23 Mil. XWELL's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €3.64 Mil.
Hence, XWELL's Days Payable for the
three
months ended in Jun. 2026 was 55.88.
The historical rank and industry rank for XWELL's Days Payable or its related term are showing as below:
STU:V9G0'
s Days Payable Range Over the Past 10 Years
Min: 19.81 Med: 37.19 Max: 255.9
Current: 51.08
During the past 13 years, XWELL's highest Days Payable was 255.90. The lowest was 19.81. And the median was 37.19.
STU:V9G0's Days Payable is ranked worse than 62.11% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.005
vs STU:V9G0: 51.08
XWELL's Days Payable
increased
from Jun. 2025 (32.53) to Jun. 2026 (55.88).
It may suggest that XWELLdelayed paying its suppliers.
The historical data trend for XWELL's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:V9G0 vs MBAI, NDRA, BIAF: Days Payable Comparison
For the Diagnostics & Research subindustry, XWELL's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XWELL Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Days Payable distribution charts can be found below:
* The bar in red indicates where XWELL's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
XWELL's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XWELL (STU:V9G0) has a Days Payable of 55.88 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on XWELL and its competitors. This is 50% above median its historical median of 37.19. Over the past decade, XWELL's Days Payable has ranged from 19.81 to 255.90. According to the industry distribution chart, XWELL ranks #118 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 62.1%.
Is XWELL's Days Payable too high?
XWELL's current Days Payable of 55.88 is 50% above median its 10-year median of 37.19. Over the past 10 years, this metric has ranged from a low of 19.81 to a high of 255.90. The Medical Diagnostics & Research industry median Days Payable is 65.01. XWELL's value of 55.88 is 14% below this industry median. Based on the distribution chart, XWELL ranks #118 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, XWELL has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does XWELL's Days Payable compare to MBAI and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, XWELL ranks #118 out of 190 companies for Days Payable. This places XWELL in the lower half of its industry. The industry median Days Payable is 65.01. XWELL's value of 55.88 is 14% below this benchmark. Historically, XWELL's own Days Payable has ranged from 19.81 to 255.90 over the past decade. While the company's 10-year median is 37.19 vs. the industry median of 65.01, XWELL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.01, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XWELL's current Days Payable of 55.88 is 14% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on XWELL and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XWELL's current Days Payable is 55.88, which is 50% above median its own 10-year median of 37.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XWELL stock overvalued right now?
XWELL (STU:V9G0) has a current Days Payable of 55.88. The stock's GF Value™ is €2.45, compared to a current price of €2.96 — trading 20.8% above its estimated fair value. The current Days Payable is 55.88, which is 50% above median its 10-year median of 37.19 and 14% below the Medical Diagnostics & Research industry median of 65.01. XWELL's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For XWELL (STU:V9G0), the current Days Payable is 55.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XWELL (STU:V9G0) Overvalued in 2026?
Based on GuruFocus' analysis, XWELL stock appears to be overvalued.
The current stock price of €2.96 is trading 20.8% above its estimated GF Value™ of €2.45.
Key valuation signals for STU:V9G0:
Days Payable: 55.88 (50% above median its 10-year median of 37.19)
GF Value™: €2.45 vs. price of €2.96 (20.8% above fair value)
Industry Position: 14% below the Medical Diagnostics & Research median (#118 of 190)
No single metric tells the full story. See the STU:V9G0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
27GF Score
Get the complete analysis for STU:V9G0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:V9G0 has been successfully added to your 
